Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 179 results for "Byetta"

Opinion/decision on a Paediatric investigation plan (PIP): ...

European Medicines Agency - Science, medicines, health An agency of the European Union Search for medicines Search European Medicines Agency, 1 day ago

2 images for "Byetta"

HealthCentral.com, 3 months ago
NewsGrio, 5 months ago
Share Market Updates

Teva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version of Byetta Exenatide Injection in the United States

By a News Reporter-Staff News Editor at Pharma Business Week Teva Pharmaceuticals USA, Inc., (NYSE and TASE:TEVA) announced that they have settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, ...
 Pharmacy Choice2 weeks ago Teva settles generic Byetta patent litigation with AstraZeneca  PharmaBiz4 weeks ago Teva and AstraZeneca settle Byetta patent fight  Seeking Alpha1 month ago TEVA PHARMACEUTICAL : Settles Patent Litigation with AstraZeneca Allowing to Commercialize Its Generic Version of Byetta┬« (Exenatide Injection) in the United States  4 Traders1 month ago
[x]  

AstraZeneca, Teva settle Byetta patent suit; generics on their way

Immediately following AstraZeneca's big FluMist setback Thursday, the British pharma has entered into an agreement with Teva that will likely lead to sales losses for another product, Byetta. AstraZeneca and Teva settled patent disputes over the ...
 CPhI.cn3 weeks ago
CPhI.cn

Major players in Type II diabetes shifting focus to pricing to maintain market share

According to a report by GlobalData, human insulins and many insulin analogs are currently off patent or will soon lose their patents The highly mature Type II diabetes (T2D) market, which is forecast to be valued at $58.7 billion by 2025, will ...
 Express Pharma4 days ago Major Players in Type 2 Diabetes Shift Focus to Pricing  CPhI.cn1 week ago GLOBALDATA : Companies prioritise competitive pricing in type 2 diabetes, says GlobalData  4 Traders2 weeks ago Type 2 Diabetes Market: Competitive Pricing to Offset Patent Expiries  PharmaceuticalProcessing2 weeks ago
[x]  
Seeking Alpha

Buy vTv Therapeutics For Its Novel Alzheimer's And Anti-Diabetic Drug Candidates.

vTv Therapeutics (NASDAQ: VTVT ) is an emerging biopharmaceutical company that is using a proprietary drug discovery engine called TTP transitional technology to develop novel drugs for common diseases like Alzheimer's disease and type 2 diabetes.
 Seeking Alpha4 days ago

The global type 2 diabetes market is projected to reach $58.7bn by 2025

The global type 2 diabetes (T2D) market is projected to reach $58.7bn by 2025, driven by competitive pricing adopted by pharmaceutical companies, according to a GlobalData report. Titled PharmaPoint: Type 2 Diabetes Global Drug Forecast and ...
 CPhI.cn6 days ago Report: Pricing to take precedence as pharmaceutical companies strive to remain profitable within mature type 2 diabetes market  Pharmaceutical Technology1 week ago
FiercePharma

Talk show host Dr. Phil has a new subject: AstraZeneca's Bydureon

Dr. Phil has some new advice. In a campaign beginning March 10, Philip McGraw, better known by his TV talk show host name Dr. Phil, will partner with AstraZeneca ($AZN) in a new diabetes awareness campaign. Dr. Phil Although AZ didn't detail ...
 FiercePharma1 week ago

Diabetes Mellitus Therapeutics Market to Reach USD 10.2 Billion in Asia Pacific By 2021 MarketIntelReports

"Type 2 Diabetes Mellitus Therapeutics Market in Asia-Pacific: Rise in the population with signs of diabetes through 2021." Type 2 Diabetes Mellitus Therapeutics Market in Asia-Pacific: Capital expenditure for R&D and production of drug for ...
 Digital Journal1 week ago India Is Home To Largest 'Diabetes' Drugs Market Worldwide  Businessworld India4 weeks ago
[x]  
FiercePharma

Lilly's dulaglutide matches Victoza in study, but the real loser is AstraZeneca's Bydureon

Novo Nordisk's Victoza--FiercePharma file photo Eli Lilly is one step closer to launching its promising new diabetes drug dulaglutide--and one step closer to putting a crimp in Novo Nordisk's big-selling rival, Victoza. Lilly unveiled top-line ...
 FiercePharma1 week ago Will GLP market growth save Novo's Victoza from Lilly's new Trulicity?  FiercePharma2 weeks ago

Diabetes Injection Pens Market Analysis, Segments, Growth and Value Chain 2016-2020

Diabetes Injection Pens Market 2016 Industry Size, Shares, Segment & Forecast up to 2020 This press release was orginally distributed by SBWire Deerfield Beach, FL -- (SBWIRE) -- 07/07/2016 -- Diabetes Injection Pens Market - Global Industry ...
 Digital Journal2 weeks ago Antidiabetics Market Volume Forecast and Value Chain Analysis 2016-2020  Digital Journal2 weeks ago Diabetes Injection Pen Market Global Sales, Ex-factory Price, Revenue, Gross Margin Analysis 2016  Press Release Ping2 weeks ago Global Diabetes Injection Pens Market Report Provides a Comprehensive View & Included a Detailed of Competitive Scenario and Product Portfolio of Key Vendors.  Digital Journal2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less